Oncology Revenue Cycle in 2026: How Drug Cost Inflation Is Reshaping Reimbursement Strategies
The oncology revenue cycle in 2026 looks very different than it did just a few years ago.
Rising drug acquisition costs, tighter payer scrutiny, evolving Medicare reimbursement rules, and growing prior authorization requirements have created a high-risk financial environment for oncology practices. With specialty drugs accounting for the majority of oncology revenue, even small reimbursement gaps can translate into significant losses.
Chemotherapy & Infusion Coding Errors That Delay Oncology Reimbursements
How Everest A/R Management Group Helps Oncology Practices Recover High-Dollar Claims Faster
Chemotherapy and infusion services drive a large share of oncology revenue—but they also carry the highest denial and delay risk in medical billing.
At Everest A/R Management Group, we consistently see oncology practices losing 15–35% of expected revenue due to avoidable chemotherapy and infusion coding errors.
Below are the most common issues—and how Everest fixes them.
Accurate Oncology Billing & Coding Solutions to Strengthen Your Revenue Cycle
In the demanding world of oncology, accuracy isn’t just important — it’s everything. From chemotherapy sessions to radiation therapy, each service requires precise documentation, coding, and billing. Yet, many oncology practices face revenue leaks, claim denials, and compliance issues due to complex billing regulations.